Literature DB >> 465291

Human pharmacology of narcotic antagonists.

D R Jasinski.   

Abstract

1 Human studies at the Addiction Research Center enable narcotic antagonists to be classified into three subgroups: (1) nalorphine-like agents; (2) pure antagonists; and (3) morphine-like agents. 2 Six narcotic antagonists (pentazocine, nalbuphine, cyclazocine, butorphanol, propiram and buprenorphine) developed in recent years seem to have a lesser abuse potential than codeine or propoxyphene. 3 When adjusted for relative availability of the agents, epidemiological data shows that pentazocine is abused less than codeine or propoxyphene in the US. 4 Recent studies with buprenorphine indicate that this agent would find application both as an analgesic of low abuse potential and as a new type of drug for the treatment of addiction.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 465291      PMCID: PMC1429310          DOI: 10.1111/j.1365-2125.1979.tb04702.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  STUDIES ON THE HUMAN ADDICTION LIABILITY OF 2'-HYDROXY-5-9-DIMETHYL-2-(3,3-DIMETHYLALLYL)-6,7-BENZOMORPHAN (WIN 20,228): A WEAK NARCOTIC ANTAGONIST.

Authors:  H F FRASER; D E ROSENBERG
Journal:  J Pharmacol Exp Ther       Date:  1964-02       Impact factor: 4.030

2.  Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.

Authors:  D R Jasinski; J S Pevnick; J D Griffith
Journal:  Arch Gen Psychiatry       Date:  1978-04

3.  Evaluation of nalbuphine for abuse potential.

Authors:  D R Jasinski; P A Mansky
Journal:  Clin Pharmacol Ther       Date:  1972 Jan-Feb       Impact factor: 6.875

4.  Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man.

Authors:  W R Martin; J W Sloan; J D Sapira; D R Jasinski
Journal:  Clin Pharmacol Ther       Date:  1971 Mar-Apr       Impact factor: 6.875

5.  Demonstration of tolerance to and physical dependence of N-allylnormorphine (nalorphine).

Authors:  W R Martin; C W Gorodetzky
Journal:  J Pharmacol Exp Ther       Date:  1965-12       Impact factor: 4.030

6.  Studies of the dependence-producing potential of the narcotic antagonist 2-cyclopropylmethyl-2'-hydroxy-5,9-dimethyl-6,7-benzomorphan (cyclazocine, WIN-20,740, ARC II-c-3).

Authors:  W R Martin; H F Fraser; C W Gorodetzky; D E Rosenberg
Journal:  J Pharmacol Exp Ther       Date:  1965-12       Impact factor: 4.030

  6 in total
  8 in total

1.  The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects.

Authors:  M W Lo; F H Lee; W L Schary; C C Whitney
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

2.  Mixed agonist-antagonist opiates and physical dependence.

Authors:  J J Jacob; G M Michaud; E C Tremblay
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

3.  The clinical assessment of analgesic drugs.

Authors:  D W Littlejohns; D W Vere
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

Review 4.  Dezocine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  J J O'Brien; P Benfield
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

Review 5.  Ketamine and phencyclidine: the good, the bad and the unexpected.

Authors:  D Lodge; M S Mercier
Journal:  Br J Pharmacol       Date:  2015-07-28       Impact factor: 8.739

Review 6.  Opioid agonist-antagonist drugs in acute and chronic pain states.

Authors:  P J Hoskin; G W Hanks
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

Review 7.  Nalbuphine. A preliminary review of its pharmacological properties and therapeutic efficacy.

Authors:  J K Errick; R C Heel
Journal:  Drugs       Date:  1983-09       Impact factor: 9.546

Review 8.  Transnasal butorphanol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute pain management.

Authors:  J C Gillis; P Benfield; K L Goa
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.